GLP-1 weight loss: what dietitians add to medication

By the DieticiansWorldwide.com editorial team · 17 October 2026 · Weight management & GLP-1

What GLP-1 medicines are

GLP-1 stands for glucagon-like peptide-1, a gut hormone released after eating. GLP-1 receptor agonists are medicines that mimic it, and some newer drugs combine GLP-1 action with a second hormone. For weight management, the two you will hear about most are:

• Semaglutide, a GLP-1 receptor agonist, sold for weight management as Wegovy. Its US label now covers a once-weekly injection and a tablet, both "in combination with a reduced calorie diet and increased physical activity" (FDA label via DailyMed, Wegovy).
• Tirzepatide, a dual GIP and GLP-1 receptor agonist, sold for weight management as Zepbound. Its label describes a starting dose of 2.5 mg once a week for 4 weeks, increased in 2.5 mg steps (FDA label via DailyMed, Zepbound).

Both labels say the medicines are indicated "to reduce excess body weight and maintain weight reduction long term" in adults with obesity, or with overweight and at least one weight-related condition. The phrase that matters for this article is the one that comes first in both: alongside a reduced-calorie diet and more activity. Nutrition is written into the licence, not added as an optional extra.

How they cause weight loss

These medicines act on appetite and fullness. People typically feel full sooner, think about food less and eat smaller portions. The Zepbound label also notes that the drug "delays gastric emptying", meaning food leaves the stomach more slowly. The weight loss comes from eating less energy, not from a special effect on fat burning. That is the central reason dietitians matter: when someone eats much less, the quality of what they do eat becomes far more important.

How much weight people lose: the trial evidence

Semaglutide: STEP 1

STEP 1 randomised 1,961 adults without diabetes to weekly semaglutide 2.4 mg or placebo, both with lifestyle intervention. At week 68, the average change in body weight was −14.9% with semaglutide against −2.4% with placebo, and half of those on semaglutide (50.5%) lost 15% or more (Wilding and colleagues, NEJM 2021). In kilograms, that was −15.3 kg against −2.6 kg.

Tirzepatide: SURMOUNT-1

SURMOUNT-1 randomised 2,539 adults with obesity or overweight, without diabetes, to three doses of tirzepatide or placebo for 72 weeks. Average weight change was −15.0% at 5 mg, −19.5% at 10 mg and −20.9% at 15 mg, against −3.1% on placebo (Jastreboff and colleagues, NEJM 2022). At the two higher doses, 50% and 57% of participants lost at least 20% of their weight.

Which GLP-1 works best for weight loss?

Only one large trial has compared the two head to head. SURMOUNT-5 randomised 751 adults with obesity but without type 2 diabetes to the maximum tolerated dose of tirzepatide or semaglutide for 72 weeks. Weight fell by 20.2% with tirzepatide and 13.7% with semaglutide, and waist circumference by 18.4 cm against 13.0 cm (Aronne and colleagues, NEJM 2025). The trial was open-label and funded by the maker of tirzepatide.

"Best" is not only about the average, though. Tolerability, other conditions, cost, insurance, supply and how a person responds all matter, and individual results vary widely around the averages. That choice belongs to the prescriber and patient. What a dietitian can influence is whether the weight lost is mostly fat, whether the person stays well nourished, and what happens to eating habits if the medicine stops.

How fast does the weight come off?

People often ask how long it takes to lose 20 pounds, or how much they can lose in three months. The trials do not answer that well, because they report results at 68 to 72 weeks and the doses are increased gradually over the first months. STEP 1 included 16 weeks of dose escalation and SURMOUNT-1 a 20-week escalation period, so early weeks are spent on lower doses. Expect a gradual process measured over a year or more, not a fixed number by a given date.

The side effects, and how diet helps

Gastrointestinal effects are the most common problem. In STEP 1, nausea and diarrhoea were the most frequent adverse events, "typically transient and mild-to-moderate", and 4.5% of people on semaglutide stopped because of them. In SURMOUNT-1, adverse events caused treatment to stop in 4.3% to 7.1% of participants depending on dose. The Zepbound label lists the most common adverse reactions as nausea, diarrhoea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, tiredness, hypersensitivity reactions, belching, hair loss and reflux.

The Wegovy label also lists less common but serious risks, including acute pancreatitis, gallbladder disease, acute kidney injury caused by dehydration, and pulmonary aspiration during general anaesthesia or deep sedation, which is why you should tell any surgical team you are taking one.

Many of the everyday effects can be eased with practical eating changes: smaller meals, eating slowly and stopping at the first sign of fullness, cutting back on very fatty or fried foods, keeping up fluids, and building fibre up gradually for constipation. Our guide to the Ozempic nausea and constipation diet goes through these in detail. Persistent vomiting, severe abdominal pain or signs of dehydration need medical attention, not diet tweaks.

Muscle loss: the real debate

When people lose weight by any method, some of what they lose is fat-free mass, which includes muscle, organs and water. The question is how much, and whether it matters.

For STEP 1, the 2025 nutrition advisory issued jointly by lifestyle medicine, nutrition and obesity societies reports that of the average 13.6 kg lost in the body-composition subgroup, 8.3 kg (62%) was fat mass and 5.3 kg (38%) was lean body mass (American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association and The Obesity Society, 2025).

A 2026 systematic review and meta-analysis compared trials with at least 10% weight loss. The proportion of weight lost as fat-free mass was 33.3% for incretin-based medicines and 34.2% for bariatric surgery, against 14.9% for diet with or without exercise. Diet without exercise lost 22.3%, while diet combined with exercise lost only 7.7% (Diabetes, Obesity and Metabolism 2026). The authors concluded that strategies to preserve fat-free mass, "particularly exercise, should be included in all weight-loss approaches".

There are two sides to this. Some loss of lean tissue is expected when the body gets smaller, and in STEP 1 people on semaglutide reported a greater improvement in physical functioning than those on placebo. Others worry about older adults, people who are already frail, and anyone who loses weight quickly while eating very little protein. Both groups agree on the practical response: enough protein, resistance exercise, and monitoring strength and function. Our dedicated article on whether GLP-1 medicines cause muscle loss looks at this debate more closely.

What dietitians add to GLP-1 treatment

The 2025 joint advisory sets out a clear role for nutrition care. It notes that guidelines recommend multicomponent nutritional and behavioural therapy for adults with obesity, "but use of such therapies with GLP-1s is not widespread", and lists registered dietitian nutritionist counselling among the supportive strategies. In practice, that work falls into five areas.

1. Assessment before starting

The advisory recommends baseline screening of usual eating habits, emotional triggers, disordered eating and relevant medical conditions, plus muscle strength, function and body composition where possible. A dietitian can spot problems that change the plan, such as a history of binge eating, a very low protein intake, or a diet already short of iron or B12.

2. Protein targets that fit a smaller appetite

According to the advisory, the general adult allowance is 0.8 g of protein per kilogram of body weight, higher intakes of 1.2 to 1.6 g/kg have been suggested while losing weight, and an absolute target of 80 to 120 g a day "may enhance adherence". It also warns that using actual body weight in people with obesity "can significantly overestimate protein requirements". A dietitian works out a sensible figure for you. As a starting point, our protein calculator gives an estimate, and the article on protein on GLP-1 medicines explains how to reach it with a reduced appetite.

3. Food quality within fewer calories

When portions shrink, every meal has to carry more nutrients. The advisory warns of nutrient deficiencies from calorie reduction and recommends minimally processed foods such as fruit, vegetables, whole grains, legumes, lean proteins, nuts and seeds, while limiting refined carbohydrates, sugar-sweetened drinks, red and processed meat and ultra-processed snacks. Our 7-day GLP-1 diet plan turns that into meals.

4. Managing side effects

Dietitians help people adjust meal size, timing, texture, fat content and fibre so that nausea, reflux and constipation are less disruptive, and recognise when symptoms need medical review.

5. Planning for maintenance, or for stopping

This is the part most often missed. In the STEP 1 extension, after treatment and the lifestyle programme stopped at week 68, participants regained 11.6 percentage points of lost weight by week 120. The authors concluded that people regained "two-thirds of their prior weight loss" within a year (Wilding and colleagues, Diabetes, Obesity and Metabolism 2022). In STEP 4, people who switched to placebo after 20 weeks gained 6.9% over the next 48 weeks, while those who stayed on semaglutide lost a further 7.9% (Rubino and colleagues, JAMA 2021). Habits built during treatment, including protein, food quality, activity and strength training, are the main tools people have if the medicine stops.

Book a session with a dietitian

Access, cost and the Medicare GLP-1 Bridge

Access rules shape who gets these medicines and how much support comes with them.

• United States, Medicare. Since 1 July 2026, the Medicare GLP-1 Bridge has let eligible Part D beneficiaries get certain GLP-1 drugs with a $50 copay, in a short-term demonstration running to 31 December 2027 (CMS). The CMS page describes drug access only; it does not mention nutrition counselling. Medicare's separate medical nutrition therapy benefit covers people with diabetes or kidney disease, not obesity alone, so people using the Bridge may need to fund dietitian support another way, as our weight-loss dietitian guide explains. More detail on US care routes is in the United States country guide.
• England, NHS. NICE recommends tirzepatide for adults with a BMI of at least 35 and at least one weight-related condition, with a lower threshold for some ethnic groups, and says to review treatment if less than 5% of weight has been lost after 6 months on the highest tolerated dose (NICE TA1026).

Compounded and online GLP-1s

FDA warns that unapproved versions of semaglutide and tirzepatide "do not undergo FDA's review for safety, effectiveness and quality". It lists red flags for online sellers, including claims that a compounded drug is the same as an approved one, prices that seem too good to be true, and no screening or prescription by a licensed doctor (FDA).

"Natural GLP-1" supplements and GLP-1 branded foods

Social media is full of supplements described as "natural GLP-1", and foods and shakes marketed as GLP-1 friendly. The joint advisory lists "dietary modulation of endogenous GLP-1" as an area needing more study, not an established treatment. No supplement has trial evidence of weight loss on the scale of the medicines above. Our evidence check on berberine as "nature's Ozempic" looks at the most popular example.

Shakes and bars can be convenient when appetite is very low, and some people use them to hit protein targets. But "GLP-1" on a label is a marketing term, not a regulated claim about effect. Our guide to meal replacement shakes explains how to judge them on protein, fibre and sugar.

Who needs extra care

• People taking insulin or a sulfonylurea. The Wegovy label warns that using it with insulin or an insulin secretagogue "may increase the risk of hypoglycemia, including severe hypoglycemia", and that their doses may need reducing. Any change must come from the prescriber.
• People planning pregnancy. The Wegovy label advises stopping at least 2 months before a planned pregnancy because of semaglutide's long half-life. The Zepbound label advises people using oral contraceptives to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and after each dose increase.
• People with a history of eating disorders. The advisory recommends screening for disordered eating before starting. A sharply reduced appetite can mask restriction.
• People with kidney disease. The labels warn of acute kidney injury from dehydration after vomiting or diarrhoea, and protein targets need adjusting in chronic kidney disease.
• Older adults. Protecting muscle and function should be a stated goal from the first appointment.
• Anyone with a personal or family history of medullary thyroid cancer or MEN 2, for whom the Wegovy label lists semaglutide as contraindicated; both labels carry a boxed warning about thyroid C-cell tumours seen in rodents.

The practical takeaway

GLP-1 medicines are among the most effective weight-loss drugs licensed so far, with average losses of 14% to 21% in the main trials. They work by helping people eat less, which makes diet quality, protein and strength training more important, not less. They also tend to be long-term treatments: stopping usually brings weight back. The best results come from treating medication and nutrition as one plan. Read more about the wider options in our weight management guide.